Preventing effect of 1.35% menthol for oxaliplatin induced neurotoxicity

Preventing effect of 1.35% menthol for oxaliplatin induced neurotoxicity - Preventing effect of 1.35% menthol for oxaliplatin induced neurotoxicity

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000009655

Enrollment

Registered

2012-12-28

Start date

2012-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

coorectal cancer

Interventions

1.35% menthol

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) ongoing oxaliplatin including chemotherapy 2) do not have neurotoxity causing other chemotherapy regimen 3) ECOG PS 0,1 4) able to use menthol 5) able to answer to questionaire 6) life expetancy over 3months 7) written informed concent

Exclusion criteria

Exclusion criteria: 1) dificult to use menthol due to other skin trouble 2) uncontrollable symptom due to cancer 3) uncontrollable symptom due to adverse events 4) other reasons causing neurotoxicity 5) not apropriate to registration

Design outcomes

Primary

Measure	Time frame
grade2 neurotoxity rate at total dose of 500mg/m2 of oxaliplatin	—

Secondary

Measure	Time frame
compliance of questionaire compliance of oxaliplatin including chemotherapy continuous rate of 1.35% menthol safety of 1.35% menthol	—

Countries

Japan

Contacts

Public ContactMasato Nakamura

Aizawa Hospital Aizawa Comprehensive Cancer Center

geka-dr7@ai-hosp.or.jp+81-263-33-8600

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026